TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a prospective phase II trial, ultralow-dose radiation—either one 4-Gy treatment or two 2-Gy treatments—was followed by a pain response in 66% of evaluable patients at four weeks and 86% at six months. Researchers reported few treatment-related adverse events and no adverse effect on bone marrow status; 19% of patients later received additional radiation.
A prospective phase II trial found that ultralow-dose radiation was followed by relief of painful bone lesions in many patients with multiple myeloma, while researchers reported few treatment-related adverse events and no adverse effect on bone marrow status. Of patients with available questionnaires, 66% had a complete or partial pain response at four weeks, rising to 86% at six months.
The 69 enrolled patients were randomly assigned to receive either one 4-Gy dose or two 2-Gy doses of radiation. Both schedules deliver substantially less radiation than the 30 Gy in 10 treatments commonly used for bone pain, according to the report. Pain response rates were similar between the two trial groups at the measured time points.
The primary outcome combined pain response with use of oral morphine-equivalent medication at four weeks. A complete response meant no pain at the treated site and no increase in medication. A partial response meant pain fell by at least two points or medication use fell by at least 25%. The 66% response at four weeks came from 61 completed questionnaires; the 64% rate at eight weeks was based on 47, and the 86% rate at six months on 42.
Five of the 69 patients had treatment-related adverse events. None were grade 3 or higher, and none led to an interruption or change in treatment. Among 63 patients assessed for retreatment, 12 (19%) received re-irradiation, at doses ranging from 8 to 24 Gy. The median time to another course was 61 days, and the reported pain response after re-irradiation was 69%.
Preserving Marrow for Ongoing Care
For people with myeloma, pain control is one part of a treatment course that may involve multiple lines of therapy. Radiation can affect blood-forming bone marrow, so limiting exposure may matter for patients who need to maintain blood counts and remain eligible for chemotherapy or future treatments. The trial authors reported that marrow status was not adversely affected, but the study does not establish that these schedules are appropriate for every patient or lesion.
Leslie Ballas, the study presenter from Cedars-Sinai Medical Center, said protecting marrow could leave room for continued chemotherapy and future options, including transplant or CAR T-cell therapy. ASTRO expert Chelsea Pinnix of MD Anderson Cancer Center said the results suggest many patients may obtain meaningful pain relief with a low initial dose. Those comments describe potential clinical implications; the trial itself was a single-arm phase II study and did not compare the approach against a control group.
ultralow-dose radiation therapy for bone pain
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Lower Doses
The study addresses painful bone lesions, a common complication of multiple myeloma. Ballas said advances in treatment have extended survival, with five-year overall survival reaching 64%, and patients may receive several therapies over their lifetimes. She also cited prior evidence that the volume of bone marrow receiving at least 10 Gy correlates with blood-related adverse events.
Earlier evidence for palliative radiation in myeloma was largely retrospective or observational, according to Ballas. A prior prospective comparison of 30 Gy with 8 Gy reported complete or partial pain responses in about 80% of patients. The new study tested whether still lower schedules could provide relief while reducing treatment burden and limiting marrow exposure. Patients with prior radiation or surgery, a long-bone fracture, spinal cord compression, or certain skull-base or orbital lesions were excluded.
“Only 19% of patients needed a second course, but it is still available to them at any point during their lifetime.”
— Leslie Ballas, MD
myeloma bone lesion pain relief products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Trial Evidence
The study was a single-arm phase II trial, and the source report does not describe a concurrent control group. Comparisons with historical results cannot establish that the low-dose schedules perform better than other approaches. The six-month response figure was based on 42 completed questionnaires, fewer than the 61 available at four weeks, so the number of patients contributing data changed over time.
The report does not give enough detail to determine whether results apply equally across different lesion locations, patient characteristics, or treatment histories. It also does not establish how long pain relief lasts beyond the reported follow-up. Although Ballas said further trials may not be necessary and that the schedules are ready for clinical practice with appropriate counseling, that is her assessment, not a universal guideline or a conclusion from a randomized comparison with standard-dose treatment.
radiation therapy pain management supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Clinical Use and Further Follow-Up
The study report presents the two schedules as potential options for appropriately selected patients, with counseling that some may require another course. Clinicians considering them would need to weigh pain, lesion features, prior treatment, marrow status, and the patient’s wider care plan. The report does not announce a next trial or specify a planned longer-term analysis.
Further reporting or publication could clarify detailed patient outcomes, differences between the one- and two-fraction schedules, and longer-term safety and pain control. For now, the findings support discussion of low-dose radiation as a possible palliative approach, while the study design and incomplete follow-up questionnaires limit how broadly its results can be applied.
bone marrow preservation radiation products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What radiation schedules did the trial test?
Patients received either one 4-Gy treatment or two treatments of 2 Gy each. The trial reported similar pain response rates between the schedules at measured time points.
How many patients had pain relief?
A complete or partial pain response was reported in 66% at four weeks and 86% at six months. Those figures were based on 61 and 42 completed questionnaires, respectively, rather than all 69 enrolled patients.
Did patients need additional radiation?
Yes. 12 of 63 patients (19%) received re-irradiation. The median time to another course was 61 days, and the reported response rate after re-irradiation was 69%.
Were serious side effects reported?
Five of 69 patients had treatment-related adverse events. None reached grade 3 or higher, and none required treatment interruption or modification. The researchers reported no adverse effect on bone marrow status.
Does the trial prove low-dose radiation is better than standard treatment?
No. The study was a single-arm phase II trial and did not include a concurrent comparison group receiving standard-dose radiation. Its findings are promising but do not prove superiority or establish that the approach fits every patient.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
